PL1928492T3 - Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby - Google Patents

Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby

Info

Publication number
PL1928492T3
PL1928492T3 PL06824878T PL06824878T PL1928492T3 PL 1928492 T3 PL1928492 T3 PL 1928492T3 PL 06824878 T PL06824878 T PL 06824878T PL 06824878 T PL06824878 T PL 06824878T PL 1928492 T3 PL1928492 T3 PL 1928492T3
Authority
PL
Poland
Prior art keywords
immunodulatory
vaccine
compounds
disease therapy
infections disease
Prior art date
Application number
PL06824878T
Other languages
English (en)
Polish (pl)
Inventor
Justin B Bertlett
George W Muller
Peter H Schafer
Christine Galutian
Angus G Dalgleish
Brendan Meyer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PL1928492T3 publication Critical patent/PL1928492T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06824878T 2005-09-01 2006-08-31 Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby PL1928492T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71282305P 2005-09-01 2005-09-01
PCT/US2006/034271 WO2007028047A2 (en) 2005-09-01 2006-08-31 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
EP06824878A EP1928492B1 (en) 2005-09-01 2006-08-31 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy

Publications (1)

Publication Number Publication Date
PL1928492T3 true PL1928492T3 (pl) 2011-09-30

Family

ID=37806889

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06824878T PL1928492T3 (pl) 2005-09-01 2006-08-31 Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby

Country Status (14)

Country Link
US (2) US8715677B2 (enExample)
EP (2) EP2301535B1 (enExample)
JP (2) JP2009507030A (enExample)
AT (1) ATE499112T1 (enExample)
CA (1) CA2621136C (enExample)
CY (1) CY1112325T1 (enExample)
DE (1) DE602006020300D1 (enExample)
DK (1) DK1928492T3 (enExample)
ES (2) ES2485316T3 (enExample)
HR (1) HRP20110348T1 (enExample)
PL (1) PL1928492T3 (enExample)
RS (1) RS51840B (enExample)
SI (1) SI1928492T1 (enExample)
WO (1) WO2007028047A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090068210A1 (en) * 2007-07-09 2009-03-12 Munshi Nikhil C Immunotherapy for hematological malignancies
US9200253B1 (en) * 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
AU2008305581C1 (en) 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US8012466B2 (en) 2008-01-31 2011-09-06 University Of Iowa Research Foundation Immunogenic compositions for activating γδ T cells
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
CA2957226C (en) 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2848493A1 (en) 2011-09-14 2013-03-21 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN105025884B (zh) * 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2981262A1 (en) 2013-04-02 2016-02-10 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3166633A1 (en) 2014-07-11 2017-05-17 Bionor Immuno AS Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
TWI727211B (zh) * 2018-09-27 2021-05-11 大江生醫股份有限公司 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途
EP4173635A4 (en) * 2020-06-26 2024-04-17 Republic of Korea (Animal and Plant Quarantine Agency) NEW IMMUNOSTIMULANT AND VACCINE COMPOSITION COMPRISING IT
CN119868399B (zh) * 2025-03-21 2025-07-11 华南农业大学 杂色曲霉胞外多糖avp141-a在制备抗石斑鱼虹彩病毒的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
WO1990011764A1 (en) * 1989-04-05 1990-10-18 Fung Peter Y S Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
CA2128331A1 (en) 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
FI990180A7 (fi) 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
WO2000055134A1 (en) 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
WO2001045750A1 (en) 1999-12-21 2001-06-28 The Regents Of The University Of California Method for preventing an anaphylactic reaction
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20030129161A1 (en) 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2003089593A2 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
DK1505973T3 (da) * 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
US20060240024A1 (en) * 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
EP1660126A1 (en) * 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table

Also Published As

Publication number Publication date
ATE499112T1 (de) 2011-03-15
JP2009507030A (ja) 2009-02-19
DE602006020300D1 (de) 2011-04-07
US20070048327A1 (en) 2007-03-01
WO2007028047A3 (en) 2007-06-14
EP2301535A1 (en) 2011-03-30
EP1928492A2 (en) 2008-06-11
SI1928492T1 (sl) 2011-09-30
RS51840B (sr) 2012-02-29
EP1928492B1 (en) 2011-02-23
DK1928492T3 (da) 2011-06-06
HRP20110348T1 (hr) 2011-07-31
EP2301535B1 (en) 2014-05-28
ES2359162T3 (es) 2011-05-19
US20120190110A1 (en) 2012-07-26
CA2621136C (en) 2014-10-14
CA2621136A1 (en) 2007-03-08
JP2013241424A (ja) 2013-12-05
ES2485316T3 (es) 2014-08-13
JP5796040B2 (ja) 2015-10-21
CY1112325T1 (el) 2015-12-09
WO2007028047A2 (en) 2007-03-08
US8715677B2 (en) 2014-05-06

Similar Documents

Publication Publication Date Title
SI1928492T1 (sl) Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
NO20052889D0 (no) Humane monoklonale antistoffer mot CD25
IL189788A0 (en) Human monoclonal antibodies to cd70
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
WO2006121810A3 (en) Trimeric ox40-immunoglobulin fusion protein and methods of use
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
GB2434367A (en) Improved vaccines
EP1800693A4 (en) ADJUVANT THERAPY USING ANTI-GLYPICAN-3 ANTIBODY
MX341775B (es) Vectores para vacunas y metodos para potenciar respuestas inmunes.
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2010017317A3 (en) Use of mtor inhibitors to enhance t cell immune responses
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
ZA200802641B (en) Human monoclonal antibodies to CD70
IL184273A0 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
WO2008034121A3 (en) Parasite vaccine
WO2003103570A3 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
UA90493C2 (ru) Альфа-тимозиновые пептиды как адьюванты противораковых вакцин
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine